News MSD, Eisai report setback in first-line kidney cancer trial The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.
News Jazz and Lilly cancer drugs cleared for use by NHS Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
News Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
News Multiple myeloma drug Blenrep backed for wider NHS use The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
News Beeline raises $300m for BMS drugs, and other biofinancings Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
News Revolution rockets on strong pancreatic cancer data Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
